艾司洛尔对脓毒性休克患者血流动力学及临床结局的影响
该研究为前瞻性随机对照试验,纳入2014年8月至2016年10月中日友好医院重症医学科脓毒性休克复苏24小时后的患者60例(实验组30例、对照组30例)。实验组持续静脉泵入艾司洛尔24小时,初始剂量0.05 mg×kg-1×h-1,滴定至心率较入组时降低20%或低于95 bpm;对照组予生理盐水3 mL/h持续24小时。结果显示实验组心率下降更明显、心脏指数和每搏量指数显著升高,平均动脉压和乳酸无差异,28天死亡率无显著差异(30.0% vs 36.7%,P=0.583)。作者认为复苏后使用艾司洛尔控制心率有效且安全,可改善心脏功能但不影响炎症因子和预后。
要点
- 脓毒性休克患者经24小时复苏后使用艾司洛尔控制心率至较入组时降低20%或低于95 bpm,可显著提高心脏指数和每搏量指数。
- 艾司洛尔初始剂量0.05 mg×kg-1×h-1持续静脉泵入24小时,心率下降更明显且不影响平均动脉压和乳酸水平。
- 实验组28天死亡率为30.0%,对照组为36.7%,两组无显著差异(χ²=0.300,P=0.583)。
- 实验组24小时白细胞介素-1β为0.15±0.06 ng/L,显著高于对照组的0.13±0.05 ng/L(P<0.01)。
- 4例患者因不能耐受艾司洛尔最低剂量、放弃治疗或24小时内死亡而退出研究。
适用人群与场景
- 2014年8月至2016年10月中日友好医院重症医学科收治的脓毒性休克患者,经24小时复苏及其他治疗后入组。
- 排除疑似急性心肌梗死、急性左心衰竭或慢性阻塞性肺疾病病史者。
处置流程与药物剂量
- 实验组:复苏24小时后持续静脉泵入艾司洛尔24小时,初始剂量0.05 mg×kg-1×h-1,滴定至心率较入组时降低20%或低于95 bpm。
- 对照组:经静脉通路给予生理盐水3 mL/h,持续24小时。
研究设计与关键结果
- 前瞻性随机对照试验,最终60例完成研究(实验组30例、对照组30例),两组性别、年龄、急性生理学与慢性健康状况评分Ⅱ及感染来源均衡可比。
- 实验组心率在给药后1、4、48小时下降较对照组更明显(bpm:97.4±16.5 vs 110.9±19.6,95.2±15.3 vs 105.1±17.9,86.4±12.1 vs 97.2±22.6,均P<0.05)。
- 实验组心脏指数在8、24、48小时显著高于对照组(mL×s-1×m-2:57.2±13.5 vs 46.5±11.0,57.7±15.7 vs 48.7±14.7,61.2±16.5 vs 51.5±14.7,均P<0.05)。
- 实验组每搏量指数在4、8、24小时显著高于对照组(mL/m2:34.1±6.9 vs 29.0±8.7,35.0±6.1 vs 28.8±9.6,38.3±10.1 vs 31.9±13.2,均P<0.05)。
- 实验组24小时白细胞介素-1β显著高于对照组(ng/L:0.15±0.06 vs 0.13±0.05,P<0.01)。
- 两组平均动脉压、乳酸、白细胞、白细胞介素-6、白细胞介素-10及肿瘤坏死因子-α无差异;28天死亡率实验组30.0% vs 对照组36.7%,无显著差异(χ²=0.300,P=0.583)。
证据类型、等级与局限
- 证据类型:前瞻性随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,脓毒性休克患者复苏后使用艾司洛尔控制心率有效且安全,可改善心脏功能而不影响血压和乳酸,但对炎症因子和预后无影响。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate the effect of heart rate control with esmolol on hemodynamics, inflammatory cytokines and clinical outcomes in patients with septic shock.
METHODS: A prospective randomized controlled trial was conducted. The patients with septic shock admitted to Department of Critical Care Medicine of China-Japan Friendship Hospital from August 2014 to October 2016 were enrolled. After 24 hours of resuscitation and other therapy, they were randomly divided into two groups by sealed envelope. The patients in experimental group was treated with continuous intravenous esmolol infusion for 24 hours, initial dose was 0.05 mg×kg-1×h-1, and was titrated to decrease the heart rate by 20% as compared with the value at the time of enrollment or below 95 bpm, while isotonic saline was given to control group through intravenous line at 3 mL/h for 24 hours. The differences in hemodynamic parameters at 0, 1, 4, 8, 12, 24 and 48 hours, as well as serum inflammatory cytokines and blood lactate (Lac) at 0, 12, and 24 hours, 28-day mortality were compared between the two groups.
RESULTS: Seventy-six septic shock patients were admitted during the study, 12 were excluded for suspicious acute myocardial infraction (AMI) or acute left heart failure or for the history of chronic obstructive pulmonary disease (COPD), 4 were quitted the study for being unable to tolerate the lowest dose of esmolol, giving up treatment, or death within 24 hours. Finally, 60 patients completed the study, 30 patients in experimental group, and 30 in control group. There were no differences in gender, age, acute physiology and chronic health evaluation II (APACHE II) score and infection source between two groups, indicating the general data between the two groups were balanced and comparable. The decrease in heart rate was more markedly in experimental group than that of control group at 1, 4, 48 hours after esmolol administration (bpm: 97.4±16.5 vs. 110.9±19.6, 95.2±15.3 vs. 105.1±17.9, 86.4±12.1 vs. 97.2±22.6, all P < 0.05), cardiac index (CI) at 8, 24, 48 hours was significantly increased (mL×s-1×m-2: 57.2±13.5 vs. 46.5±11.0, 57.7±15.7 vs. 48.7±14.7, 61.2±16.5 vs. 51.5±14.7, all P < 0.05), and stroke volume index (SVI) at 4, 8, 24 hours was significantly increased (mL/m2: 34.1±6.9 vs. 29.0±8.7, 35.0±6.1 vs. 28.8±9.6, 38.3±10.1 vs. 31.9±13.2, all P < 0.05). Interleukin-1β (IL-1β) at 24 hours in experimental group was significantly higher than that of control group (ng/L: 0.15±0.06 vs. 0.13±0.05, P < 0.01). There were no differences in mean arterial pressure (MAP), Lac, white blood cell (WBC), IL-6, IL-10, and tumor necrosis factor-α (TNF-α) between the two groups, and no difference in 28-day mortality between experimental group and control group was found (30.0% vs. 36.7%,χ 2 = 0.300, P = 0.583).
CONCLUSIONS: It is efficient and safe to use esmolol for heart rate control in patients with septic shock after resuscitation. Esmolol can improve cardiac performance without affecting blood pressure and Lac, but has no effect on inflammatory cytokines and prognosis.
参考来源
- Wang S, Li M, Duan J, et al. [Effect of esmolol on hemodynamics and clinical outcomes in patients with septic shock]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2017. PMID: 28524025. doi:10.3760/cma.j.issn.2095-4352.2017.05.002
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。